Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:17:32.799Z.
Consensus retrieved: 2026-10-06T13:46:33.897Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:17:32.799Z.
Quote observation: 2026-10-06T19:14:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c3dbe71a0fe55431d15913f230b0583615770e6f1642b2e59d58eeac51dced7
Forward PE Ratio (N/A) = Dated Quote Price ($0.45) / Consensus Forward EPS ($-3.27)
FORWARD PE RATIO
N/A
Moleculin Biotech, Inc.
Market Cap
$2.39M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | $2.39M | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.41M | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.42M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.43M | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.44M | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.33M | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.53M | N/A |
| Nuwellis, Inc. (NUWE)vs › | $2.57M | N/A |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.16M | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.15M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.45, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.27 | $-3.36 – $-3.17 | 2 | n/m |
| 2027-12-31 | $-1.17 | $-1.62 – $-0.71 | 2 | n/m |
| 2028-12-31 | $-1.32 | $-1.60 – $-1.04 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
